{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"MagnetisMM-9","nct_id":"NCT05014412","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=magnetismm-9-nct05014412. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MagnetisMM-9","arms":[{"description":"Evaluation of step-up priming dosing","label":"Part 1","type":"EXPERIMENTAL"},{"description":"Dose determination","label":"Part 2A","type":"EXPERIMENTAL"},{"description":"Dose expansion","label":"Part 2B","type":"EXPERIMENTAL"},{"description":"To explore higher dose intensity","label":"Part 2C","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-12-12","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":86,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Elranatamab","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-10","lead_sponsor":"Pfizer","official_title":"A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-06-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2","timeFrame":"Parts 1 and 2: Cycle 1 (28 days)"}],"references":[{"citation":"Hibma JE, Irby D, Liu A, Elmeliegy M, King LE, Gifondorwa D, Jiang S, Poels KE, Soltantabar P, Lon HK, Shtylla B, Wang D, Williams JH, Nicholas T. Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet. 2026 Aug;65(8):1173-1192. doi: 10.1007/s40262-026-01663-z. Epub 2026 Jun 13.","pmid":"42287565","type":"DERIVED"},{"citation":"Lon HK, Hibma J, Jiang S, Sullivan S, Vandendries E, Skoura A, Wang D, Elmeliegy M. Population Exposure-Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma. Target Oncol. 2025 Sep;20(5):803-819. doi: 10.1007/s11523-025-01168-y. Epub 2025 Aug 18.","pmid":"40826257","type":"DERIVED"},{"citation":"Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Conte U, Irby D, Hibma J, Lon HK, Piscitelli J, Soltantabar P, Skoura A, Jiang S, Wang D. Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma. Target Oncol. 2025 Mar;20(2):349-359. doi: 10.1007/s11523-025-01134-8. Epub 2025 Feb 25.","pmid":"40000533","type":"DERIVED"}],"start_date":{"date":"2021-10-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment","url":"https://clinicaltrials.gov/study/NCT05014412"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/magnetismm-9-nct05014412"}